# A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Older Adults in Korea

> **NCT06593587** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 378 (actual)

## Conditions studied

- Respiratory Syncytial Virus

## Interventions

- **BIOLOGICAL:** RSVpreF Vaccine
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06593587
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-10-07
- **Primary completion:** 2025-02-03
- **Final completion:** 2025-02-03
- **Target enrollment:** 378 (ACTUAL)
- **Last updated:** 2026-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06593587

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06593587, "A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Older Adults in Korea". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06593587. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*